目的 探究羅沙司他膠囊聯(lián)合左卡尼汀注射液治療腎性貧血的臨床療效。方法 選取2022年3月—2023年3月鹽城市第三人民醫(yī)院收治的80例腎性貧血患者，按照隨機數(shù)表法將所有患者分為對照組和治療組，每組各40例。對照組皮下注射重組人促紅素注射液（CHO細(xì)胞），80～120 U/kg，2～3次/周，隨后于血透結(jié)束后取0.9%氯化鈉溶液10 mL與1.0 g左卡尼汀注射液混合后靜脈注射，2～3次/周。治療組口服羅沙司他膠囊，體質(zhì)量40～60 kg者予以100 mg，體質(zhì)量＞60 kg者予以120 mg，后續(xù)依據(jù)血紅蛋白（Hb）水平調(diào)整劑量，3次/周。于血透結(jié)束后取0.9%氯化鈉溶液10 mL與1.0 g左卡尼汀注射液混合后靜脈注射，2～3次/周。兩組均連續(xù)治療12周。觀察兩組達標(biāo)率，比較兩組患者治療前后貧血、鐵代謝指標(biāo)。結(jié)果 治療后，兩組的達標(biāo)率分別為57.50%、80.00%，差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組患者的Hb、紅細(xì)胞壓積（Hct）、紅細(xì)胞計數(shù)（RBC）均升高，差異有統(tǒng)計學(xué)意義（P＜0.05）；且治療組的Hb、Hct、RBC均高于對照組，差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組患者的血清鐵（SI）、不飽和鐵結(jié)合力（UIBC）、血清鐵飽和度（ISAT）均升高，不飽和鐵結(jié)合力（UIBC）降低，差異有統(tǒng)計學(xué)意義（P＜0.05）；且治療組的SI、TIBC、ISAT均高于對照組，UIBC低于對照組，差異有統(tǒng)計學(xué)意義（P＜0.05）。結(jié)論 羅沙司他膠囊聯(lián)合左卡尼汀注射液可有效糾正腎性貧血患者貧血情況，促進鐵的吸收和利用。

Objective To explore the effect of Roxadustat Capsules combined with Levocarnitine Injection in treatment of renal anemia. Methods Patients (80 cases) with renal anemia in Yancheng Third People’s Hospital from March 2022 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 40 cases. Patients in the control group were sc administered with Recombinant Human Erythropoietin Injection (CHO Cell), 80～120 U/kg, 2 — 3 times weekly. After hemodialysis, 1.0 g Levocarnitine Injection added into 0.9% sodium chloride solution 10 mL, 2 — 3 times weekly. Patients in the treatment group were po administered with Roxadustat Capsules, those with a body weight of 40 — 60 kg were given 100 mg, those with a body weight of > 60 kg were given 120 mg, and the dose was subsequently adjusted according to Hb level, 3 times weekly. After hemodialysis, 1.0 g Levocarnitine Injection added into 0.9% sodium chloride solution 10 mL, 2 — 3 times weekly. Patients in two groups were treated for 12 weeks. After treatment, compliance rates were evaluated, and the anemia indicators and the metabolism indexes in two groups were compared. Results After treatment, compliance rates of the two groups were 57.50% and 80.00%, respectively, with statistical significance (P < 0.05). After treatment, Hb, Hct, and RBC of two groups were increased, and the difference was statistically significant (P < 0.05). After treatment, Hb, Hct, and RBC in the treatment group were higher than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, SI, TIBC, and ISAT in two groups were increased, while UIBC in two groups was decreased, with statistical significance (P < 0.05). After treatment, SI, TIBC, and ISAT in the treatment group were higher than those in the control group, but UIBC in the treatment group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Roxadustat Capsules combined with Levocarnitine Injection can effectively correct anemia in patients with renal anemia and promote iron absorption and utilization.

R973